Simultaneous resection of a bladder tumor and prostate is oncologically and functionally safe
dc.authorscopusid | 50361472100 | |
dc.authorscopusid | 57212306040 | |
dc.authorscopusid | 11238972400 | |
dc.authorscopusid | 56240034100 | |
dc.authorscopusid | 8649992200 | |
dc.authorscopusid | 6602590134 | |
dc.contributor.author | Kizilay F. | |
dc.contributor.author | Sahin M. | |
dc.contributor.author | Turna B. | |
dc.contributor.author | Altay B. | |
dc.contributor.author | Nazli O. | |
dc.contributor.author | Semerci B. | |
dc.date.accessioned | 2023-01-12T20:26:49Z | |
dc.date.available | 2023-01-12T20:26:49Z | |
dc.date.issued | 2020 | |
dc.department | N/A/Department | en_US |
dc.description.abstract | Objective: The aim of this study is to compare the outcomes of patients who underwent simultaneous transurethral resection of the prostate (TURP) and transurethral resection of bladder tumor (TURBT) with those who underwent only TURBT. Design: Historical-cohort Setting: Department of Urology, Ege University School of Medicine, Turkey Subjects: One hundred and eighty-six patients who underwent TUR were included in the study. Intervention: Tumor characteristics, complication, recurrence and progression rates, recurrence localizations, and elapsed time to recurrence were compared between the groups. Main outcome measures: Outcomes of simultaneous resection Results: The bladder tumor recurrence rate was 36.6% for group A and 29.8% for group B (P=.068), and the progression rates were 8.2% and 6.4%, respectively (P=.084). There was no significant difference between the elapsed time to recurrence (8.28±1.17 vs. 6.54±1.28 months) and the rate of prostatic urethral recurrence (1.8% vs. 1.7%, P=.712 and P=.395, respectively). Complication rates and progression distribution of tumors were also similar in both groups. Conclusion: It is safe to resect an incidentally detected bladder tumor along with prostate resection, with similar rates of progression, recurrence, and complications. © 2020, Kuwait Medical Association. All rights reserved. | en_US |
dc.identifier.endpage | 273 | en_US |
dc.identifier.issn | 00235776 | |
dc.identifier.issn | 0023-5776 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.scopus | 2-s2.0-85090594672 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.startpage | 268 | en_US |
dc.identifier.uri | https://hdl.handle.net/11454/80115 | |
dc.identifier.volume | 52 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.language.iso | en | en_US |
dc.publisher | Kuwait Medical Association | en_US |
dc.relation.ispartof | Kuwait Medical Journal | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Benign prostatic hyperplasia | en_US |
dc.subject | Bladder tumor | en_US |
dc.subject | Progression | en_US |
dc.subject | Recurrence | en_US |
dc.subject | Transurethral resection | en_US |
dc.subject | cefazolin | en_US |
dc.subject | furosemide | en_US |
dc.subject | adult | en_US |
dc.subject | Article | en_US |
dc.subject | bladder cancer | en_US |
dc.subject | bladder tumor | en_US |
dc.subject | blood transfusion | en_US |
dc.subject | cancer growth | en_US |
dc.subject | cancer localization | en_US |
dc.subject | cancer recurrence | en_US |
dc.subject | cancer staging | en_US |
dc.subject | cohort analysis | en_US |
dc.subject | cystectomy | en_US |
dc.subject | cystoscopy | en_US |
dc.subject | endoscopy | en_US |
dc.subject | female | en_US |
dc.subject | fever | en_US |
dc.subject | follow up | en_US |
dc.subject | hematuria | en_US |
dc.subject | human | en_US |
dc.subject | hypertension | en_US |
dc.subject | International Prostate Symptom Score | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | middle aged | en_US |
dc.subject | nuclear magnetic resonance imaging | en_US |
dc.subject | outcome assessment | en_US |
dc.subject | postoperative complication | en_US |
dc.subject | postvoid residual urine volume | en_US |
dc.subject | prostate hypertrophy | en_US |
dc.subject | prostate tumor | en_US |
dc.subject | prostate urethra | en_US |
dc.subject | prostatectomy | en_US |
dc.subject | spinal anesthesia | en_US |
dc.subject | transitional cell carcinoma | en_US |
dc.subject | transurethral resection | en_US |
dc.subject | tumor recurrence | en_US |
dc.subject | urinary tract infection | en_US |
dc.subject | urine culture | en_US |
dc.subject | urine retention | en_US |
dc.subject | uroflowmetry | en_US |
dc.title | Simultaneous resection of a bladder tumor and prostate is oncologically and functionally safe | en_US |
dc.type | Article | en_US |